Celgene International Sárl (CELG) Two Studies Evaluating the Combination of REVLIMID® and rituximab in Non-Hodgkin’s Lymphomas Presented at International Conference on Malignant Lymphoma
6/20/2013 9:09:25 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from two studies evaluating the combination of REVLIMID® (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas were presented at the 12th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland.
Help employers find you! Check out all the jobs and post your resume.